What is the 13F Pro Quality Score for MNOV?

13F Pro ranks MEDICINOVA INC (MNOV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MNOV's current score at https://13fpro.ai/research/MNOV (free sign-up required for the full ranking).

Which hedge funds own the most MNOV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MNOV include Essex Woodlands Management,, BlackRock,, CITIGROUP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MNOV as soon as new 13F filings post.

Where does 13F Pro source MNOV data?

All MEDICINOVA INC fundamentals and ownership data come directly from SEC EDGAR. MEDICINOVA INC files with the SEC under CIK 1226616. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MNOV in?

MEDICINOVA INC (MNOV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MNOV research updated on 13F Pro?

MNOV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MEDICINOVA INC(MNOV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1226616 MNOV stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MNOV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MEDICINOVA INC (MNOV), a Healthcare sector company. MNOV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), MEDICINOVA INC reports quarterly revenue of $187.0K, net income of $-2.6M, free cash flow of $-3.5M. Top institutional holders of MNOV by reported 13-F value include Essex Woodlands Management,, BlackRock,, CITIGROUP, based on the most recent SEC filings. MNOV trades on the Nasdaq exchange and files with the SEC under CIK 1226616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MEDICINOVA INC directly from SEC EDGAR.

Revenue

Q1 2026

$187.0K

Net Income

Q1 2026

$-2.6M

Free Cash Flow

Q1 2026

$-3.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$409.7KFY 2025

FY20 —FY23 $1.0MFY24 —FY25 $409.7K

Net Income

-8.6% YoY

$-12.0MFY 2025

FY20 $-13.9MFY23 $-8.6MFY24 $-11.0MFY25 $-12.0M

Operating Income

-4.8% YoY

$-13.3MFY 2025

FY20 $-14.2MFY23 $-9.9MFY24 $-12.7MFY25 $-13.3M

EPS (Diluted)

-4.3% YoY

$-0.24FY 2025

FY20 —FY23 $-0.17FY24 $-0.23FY25 $-0.24

Total Assets

-18.4% YoY

$45.6MFY 2025

FY20 $75.4MFY23 $66.3MFY24 $55.9MFY25 $45.6M

Op. Cash Flow

+7.8% YoY

$-9.8MFY 2025

FY20 $-10.8MFY23 $-7.4MFY24 $-10.6MFY25 $-9.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2017
Revenue	$409.7K	—	$1.0M	—	—	—
Net Income	$-12.0M -8.6%	$-11.0M -28.9%	$-8.6M +38.1%	$-13.9M -7.0%	$-12.9M -15.9%	$-11.2M
Operating Income	$-13.3M -4.8%	$-12.7M -28.0%	$-9.9M +30.2%	$-14.2M -1.0%	$-14.0M -7.7%	$-13.0M
EPS (Diluted)	$-0.24 -4.3%	$-0.23 -35.3%	$-0.17	—	—	—
Total Assets	$45.6M -18.4%	$55.9M -15.7%	$66.3M -12.1%	$75.4M -4.8%	$79.2M +82.4%	$43.4M
Operating Cash Flow	$-9.8M +7.8%	$-10.6M -43.2%	$-7.4M +31.4%	$-10.8M -18.6%	$-9.1M -31.8%	$-6.9M

AI Insight: MNOV Financial Trends

MNOV remains pre-revenue with consistent $3M quarterly losses, equity eroding 32% from $57M to $39M over eight quarters.

• Revenue remains negligible at $0M across reported periods; company is entirely cash-burn stage with no commercial traction.

• Equity declined from $57M in Q2 2024 to $39M in Q1 2026—18% erosion in just one year amid consistent $3M net losses.

• Operating cash outflow stable at $2–4M quarterly; no debt reported, indicating burn funded by balance sheet depletion.

⚠ At current burn rate of ~$12M annually, equity runway is ~3.25 years; need for capital raise or revenue inflection looming.

⚠ Lack of revenue growth or milestone progress visible in financials; pipeline advancement and clinical data critical.

AI Insight: MNOV Ratio Trends

MedicinNova remains deeply unprofitable with all return metrics negative; ROE and ROIC show modest improvement from mid-2025 lows but trajectory remains destructive.

• ROE recovered from -28.0% in Q2 2025 to -26.2% in Q1 2026; ROIC similarly improved from -30.8% to -28.8% over same span.

• All return metrics (ROE, ROA, ROIC) remain deeply negative across entire period; company destroyed shareholder value every quarter.

⚠ ROE and ROIC deteriorated sharply Q1–Q2 2025 (from -22.9% to -28.0%), then stabilized; underlying profitability drivers need clarification.

⚠ Recent improvement from mid-2025 trough fragile; company must demonstrate sustained positive operating performance to restore value creation.

Get alerted when MNOV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MEDICINOVA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MNOV

Essex Woodlands Management, Inc.
$1.5M1,105,941 sh
BlackRock, Inc.
$967.2K705,954 sh
CITIGROUP INC
$870.9K635,715 sh
VANGUARD CAPITAL MANAGEMENT LLC
$837.1K611,039 sh
GEODE CAPITAL MANAGEMENT, LLC
$745.3K543,843 sh
VANGUARD FIDUCIARY TRUST CO
$384.5K280,621 sh
UBS Group AG
$304.4K222,200 sh
STATE STREET CORP
$265.4K193,698 sh
RENAISSANCE TECHNOLOGIES LLC
$260.2K189,900 sh
BARCLAYS PLC
$223.2K162,900 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$1.5M	1,105,941
BlackRock, Inc.	$967.2K	705,954
CITIGROUP INC	$870.9K	635,715
VANGUARD CAPITAL MANAGEMENT LLC	$837.1K	611,039
GEODE CAPITAL MANAGEMENT, LLC	$745.3K	543,843
VANGUARD FIDUCIARY TRUST CO	$384.5K	280,621
UBS Group AG	$304.4K	222,200
STATE STREET CORP	$265.4K	193,698
RENAISSANCE TECHNOLOGIES LLC	$260.2K	189,900
BARCLAYS PLC	$223.2K	162,900

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MNOV on your watchlist

Track score changes the day MEDICINOVA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MNOV a good stock to buy?

13F Pro's AI-powered analysis of MEDICINOVA INC (MNOV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNOV are available on the MNOV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MNOV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNOV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MEDICINOVA INC's investment landscape.